CLIA
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking high or moderate categorization of 510(k)-exempt in vitro diagnostics under the Clinical Laboratory Improvement Amendments of 1988 should send two copies of the product insert with regulation number citation, classification, and product code to FDA's Division of Clinical Laboratory Devices, according to a draft guidance released Aug. 14. Comments on administrative procedures for CLIA waiver and categorization are due in 90 days
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.